The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Novel treatments and ongoing clinical trials for WM: targeted agents and immunotherapies
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses novel treatment options being explored for patients with Waldenström’s macroglobulinemia (WM). Targeted agents represent one approach, with ongoing research exploring the use of non-covalent BTK inhibitors, next-generation BCL2 inhibitors, and BTK degraders in this disease setting. Immunotherapeutic strategies, including antibody-drug conjugates (ADCs), CAR-T cells, and bispecific antibodies, may provide another valuable option for patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
